Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study

A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler ® is the first inhaled corticosteroid/long-acting ꞵ2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment of asthma in adults inadequately controlled on ICS/LABA combination. In patients with asthma and persistent airflow limitation (PAL), maxim al treatment, especially with combination is suggested. This post hoc analysis of data from the IRIDIUM study assessed the efficacy of MF/IND/GLY in asthma patients with and without PAL.

Source: Respiratory Medicine - March 8, 2023 Category: Respiratory Medicine Authors: Richard N. Van Zyl-Smit, Huib AM. Kerstjens, Jorge F. Maspero, Konstantinos Kostikas, Motoi Hosoe, Ana- Maria Tanase, Peter D'Andrea, Karen Mezzi, Dominic Brittain, David Lawrence, Kenneth R. Chapman Tags: Original Research Source Type: research